Gene · 64783
Papers2,224
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 2,224
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Targeting the RNA-binding motif protein 15 suppresses prostate cancer progression and hormone therapy resistance by promoting androgen receptor degradation. | Mol Biomed | 2026 | 41949706 | PubTator, text mining | PubMed |
| RBM15 drives bladder cancer progression through YTHDF2-dependent m6A-mediated regulation of ZO2. | J Exp Clin Cancer Res | 2026 | 41913267 | PubTator, text mining | PubMed |
| Regulatory role and subtype analysis of m6A modifications in dermatomyositis. | Glob Med Genet | 2026 | 41891117 | PubTator, text mining | PubMed |
| Reduced YTHDF2 inhibits PD-L1 expression by stabilizing m6A-containing SPOP mRNA in colorectal cancer. | Cell Death Dis | 2026 | 41872151 | PubTator, text mining | PubMed |
| Differences in the expression profiles of m6A-related genes and the prognostic role in immunotherapy for lung adenocarcinoma patients. | Front Oncol | 2026 | 41809822 | PubTator, text mining | PubMed |
| The STAT3-ZEB1 axis contributes to CCL2-mediated resistance to osimertinib in lung cancer. | Front Oncol | 2026 | 41800052 | PubTator, text mining | PubMed |
| LncRNAs: key regulators and molecular mechanisms in lung cancer radiosensitivity. | Open Med (Wars) | 2026 | 41798908 | PubTator, text mining | PubMed |
| RBM15B promotes hepatocellular carcinoma progression via IGF2BP1-mediated ITSN2 mRNA stabilization. | J Cancer Res Clin Oncol | 2026 | 41795047 | PubTator, text mining | PubMed |
| Identification of FTO as a key m6A demethylase linking immune dysregulation to sepsis pathogenesis. | Front Immunol | 2026 | 41789088 | PubTator, text mining | PubMed |
| Lactylation in urological malignancies: emerging mechanisms and therapeutic direction. | Front Cell Dev Biol | 2026 | 41768991 | PubTator, text mining | PubMed |
| The emerging role of m6A methylation in prostate-related diseases: mechanisms and clinical implications. | Front Immunol | 2026 | 41766860 | PubTator, text mining | PubMed |
| Transcriptional and epigenetic reprogramming, lineage plasticity and therapy resistance in prostate cancer. | J Natl Cancer Cent | 2026 | 41738031 | PubTator, text mining | PubMed |
| The Intersection of m6A Methylation and Immune Response in PCOS: A Bioinformatics Perspective. | Immun Inflamm Dis | 2026 | 41725222 | PubTator, text mining | PubMed |
| Mechanisms at the Intersection of lncRNA and m6A Biology. | Noncoding RNA | 2026 | 41718093 | PubTator, text mining | PubMed |
| m6A demethylase-driven reprogramming of leukemia-associated macrophages predicts improved outcomes in acute myeloid leukemia. | Front Immunol | 2026 | 41710900 | PubTator, text mining | PubMed |
| RNA-binding motif protein 15 promotes gastric cancer growth and drug resistance via USP10-mediated deubiquitination and stabilization of nuclear NRF2. | Drug Resist Updat | 2026 | 41702032 | PubTator, text mining | PubMed |
| Structural characterization of endogenous microprotein EMBOW reveals an alternative MRT motif for WDR5-interacting site recognition. | FEBS J | 2026 | 41689289 | Swiss-Prot, curated | PubMed |
| Mechanism of RBM15 in Regulating PD-L1-Mediated Immune Escape in Ovarian Cancer Through the JAK2/STAT3/STAT5 Pathway. | Arch Immunol Ther Exp (Warsz) | 2026 | 41686430 | PubTator, text mining | PubMed |
| RBM15 in diseases: Molecular mechanisms and clinical opportunities from RNA m6A methylation. | Genes Dis | 2026 | 41674656 | PubTator, text mining | PubMed |
| PRMT5 inhibits the ferroptosis of hepatocellular carcinoma via regulating RBM15/FTH1 signaling. | Am J Cancer Res | 2026 | 41657808 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/64783/papers?page=2